Digestive Disease Week

Digestive Disease Week

Source:

Sands B, et al. Abstract 132. Presented at: Digestive Disease Week; May 21-23 (virtual meeting).

Disclosures: Sands reports consulting for AbbVie, Bacainn Therapeutics, Boehringer-Ingelheim, Boston Pharmaceuticals, Celltrion Healthcare, Genentech, Gilead Sciences, GlaxoSmithKline, InDex Pharmaceuticals, Inotrem, Janssen, Johnson & Johnson, Kallyope, Pfizer, Protagonist Therapeutics, Surrozen and Takeda Pharmaceuticals; serving on an advisory committee or review panel for Abivax, Arena Pharmaceuticals, Immunic, Ironwood Pharmaceuticals, Lilly, Prometheus Biosciences IBD and Target RWE. Please see the study for all other authors’ relevant financial disclosures.
June 10, 2021
1 min watch
Save

VIDEO: Mirikizumab safe, effective in Crohn’s disease treatment

Source:

Sands B, et al. Abstract 132. Presented at: Digestive Disease Week; May 21-23 (virtual meeting).

Disclosures: Sands reports consulting for AbbVie, Bacainn Therapeutics, Boehringer-Ingelheim, Boston Pharmaceuticals, Celltrion Healthcare, Genentech, Gilead Sciences, GlaxoSmithKline, InDex Pharmaceuticals, Inotrem, Janssen, Johnson & Johnson, Kallyope, Pfizer, Protagonist Therapeutics, Surrozen and Takeda Pharmaceuticals; serving on an advisory committee or review panel for Abivax, Arena Pharmaceuticals, Immunic, Ironwood Pharmaceuticals, Lilly, Prometheus Biosciences IBD and Target RWE. Please see the study for all other authors’ relevant financial disclosures.
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Mirikizumab demonstrated sustained safety and efficacy at 52-weeks in patients with Crohn’s disease; these data support the ongoing VIVID phase 3 study, Bruce Sands, MD, Icahn School of Medicine told Healio Gastroenterology.

“Mirikizumab treatment demonstrated durable endoscopic and symptomatic efficacy after a year of treatment in patients with CD and the safety profile of mirikizumab treatment was consistent with what we know of this class with few discontinuations in the re-randomized maintenance group,” Sands said. “[These] phase 2 data support continued characterization of mirikizumab efficacy and safety.”